Update on Sculptra (New-Fill) Hearing
March 26, 2004
On March 25 an FDA advisory panel unanimously recommended that the FDA approve Sculptra (New-Fill) for facial wasting caused by HIV treatment or HIV. They also want restrictions so that it will not be used widely for less urgent purposes like filling wrinkles, unless the company (Dermik Laboratories) comes back with data to support that use. The committee was not happy with the limited amount of data available, but was moved by HIV patients' testimony about their need for the treatment.
This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.